ClinicalTrials.gg
Not yet recruitingNCT07599020Updated May 20, 2026

Measuring the Changes of the Intraocular Pressure After Corneal Cross Linking Using Corvis CT

An interventional study of Corvis Machine in Keratoconus and Intraocular Pressure, sponsored by Tanta University. Not yet recruiting. Open to participants aged 19 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by Tanta University · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
19 Years to 35 Years
Sex
All
01

Study summary

To evaluate the changes that occur in the intraocular pressure before and after corneal cross linking using Corvis CT.

Read the detailed description

This study will be prospective study. 50 Patients will be included who will undergo corneal cross linking from the out-patient clinic of Tanta University hospital between December 2025 and December 2026 will be included in the study .

Patient with age 19 till 35 years old will be included

Patient with Corneal scarring, Previous corneal infections, Minimum corneal thickness at the thinnest location less than 400 µm, History of uveitis or ocular allergy and Pre-existing glaucoma will be excluded from the study

All patient will undergo full ophthalmological examination. including best corrected visual acuity, degree of myopia , average kertometry and intraocular pressure will be measured before and after cross linkage with three different techniques including Shiotz tonometry, appalanation tonometry and CORVIS machine

02

Conditions studied

  • Keratoconus
  • Intraocular Pressure

Browse trials for

03

In context

Keratoconus

313 studies on the registry are indexed under Keratoconus; 56 are open to participants now.

This study's planned enrollment of 1 is below the median of 40 across 205 interventional studies indexed under Keratoconus.

Browse Keratoconus studies →

Lead sponsor

Tanta University is the lead sponsor of 1,010 studies on the registry; 321 are open to participants now.

Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who will corneal cross linking for mild degree of keratoconus, age between 19 and 35 years old

Exclusion criteria

Exclusion Criteria:

  • Corneal scarring.
  • Previous corneal infections.
  • Minimum corneal thickness at the thinnest location less than 400 µm.
  • History of uveitis or ocular allergy.
  • Pre-existing glaucoma.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (estimated)

Study arms

  • Other
    Measuring the intraocular pressure after cross linking

    Measuring the intraocular pressure by using different techniques after corneal cross linking

    Device: Corvis Machine

Interventions

  • DeviceCorvis Machine

    Measuring the intraocular pressure

06

What researchers measure

Primary outcomes

  1. Intraocular pressure will be measured by using Corvis CT before cross linking and one month after cross linking

    Recording the intraocular pressure

    Time frame: Through the end of the study in approximately one year

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The statistical analysis results will be shared through the manuscript

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Dec 2026, 5 months later.

Of 59 non-industry interventional studies with no phase under Keratoconus, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 54. This study's planned 5 months is below that.

Counting every sponsor, half of 68 studies reached it within 34 months; a quarter within 12 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2026
First posted
May 20, 2026
StartEst.
Jul 10, 2026
Primary completionEst.
Dec 12, 2026
CompletionEst.
Feb 10, 2027
Last update
May 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07599020
Lead sponsor
Tanta University
Responsible party
Dina Tadros (Assistant professor of ophthalmology, Tanta University) — Principal investigator
First posted
May 20, 2026
Start date
Jul 10, 2026 (estimated)
Primary completion
Dec 12, 2026 (estimated)
Completion
Feb 10, 2027 (estimated)
Last update
May 20, 2026

Study contacts

Tamer Ibrahim, Ass professor of ophthalmology
Contact
dinasabry71@gmail.com
+201001243049

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion